Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - DSM Biologics

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods, such as medicines, medical devices, and blood products, are safe and of high quality for the Australian public. This legislation was introduced to address the need for comprehensive regulation and oversight of therapeutic goods to protect public health. The Therapeutic Goods Administration, operating under the auspices of the Department of Health, administers the Act. The overarching policy objective is to safeguard the health and safety of the public by regulating the therapeutic goods market effectively. In this context, the Act provides a framework for the licensing of manufacturers, thereby ensuring that only those entities meeting stringent quality and safety standards are permitted to produce therapeutic goods. The publication of the list of manufacturers granted licences, such as the one for DSM Biologics Company Australia Pty Ltd, exemplifies the commitment to transparency and accountability in maintaining high standards within the industry.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Department of Health, pertains to the regulation of therapeutic goods in Australia. This Act applies to entities such as manufacturers, importers, and suppliers of therapeutic goods, including medicines, medical devices, blood, and tissues. The legislation encompasses a wide range of therapeutic goods, ensuring they meet safety, quality, and efficacy standards before being made available in the Australian market. The Act applies across the entire Commonwealth of Australia, including states and territories, thereby establishing a unified regulatory framework for therapeutic goods nationwide. The Act sets out specific requirements and processes for the manufacture, import, supply, and advertising of therapeutic goods, with the overarching aim of protecting public health. Notably, the Act provides for the granting of licences to entities that meet the regulatory criteria, as evidenced by the publication of the licence granted to DSM Biologics Company Australia Pty Ltd, indicating compliance with the Act's standards. Any exclusions or exemptions from the provisions of the Act are specified within the legislation or through subordinate instruments, which may further refine the application of the Act to particular goods or processes.

Key Provisions

Section 38 of the Therapeutic Goods Act 1989 (the "Act") provides the legal framework for granting licences to entities that wish to manufacture therapeutic goods in Australia. This section allows the Secretary of the Department of Health, Therapeutic Goods Administration to grant a licence to an entity if they are satisfied that the entity meets the necessary standards and requirements for manufacturing therapeutic goods. Specifically, the Act requires that the premises where the goods will be manufactured are suitable, that the manufacturing process is compliant with good manufacturing practices, and that the entity has adequate quality control systems in place. The licence also stipulates the specific therapeutic goods that the entity is permitted to manufacture. Entities granted a licence under Section 38 must adhere to several key obligations and requirements. These include maintaining records of all manufacturing activities, ensuring that the premises and equipment used for manufacturing meet hygiene and safety standards, and conducting regular quality checks to ensure the therapeutic goods meet required standards. Furthermore, licensed manufacturers must report any adverse events or quality issues related to their products to the Therapeutic Goods Administration promptly. The Act also requires these entities to submit annual reports detailing their manufacturing activities and compliance status. Failure to comply with the obligations and requirements set out in the Act can lead to serious consequences. Under Section 120 of the Act, any person who contravenes the Act, or any condition of their licence, can be subjected to enforcement actions. These actions can include the suspension or cancellation of their licence, fines, or even criminal prosecution. The specific penalties vary depending on the nature and severity of the breach but can include substantial fines for corporations and imprisonment for individuals. The Act also allows for civil penalties where appropriate, which can be pursued by the Therapeutic Goods Administration to ensure compliance and protect public health.